Correlation of PET-CT with OAR dose from radiotherapy

  • Research type

    Research Study

  • Full title

    Correlation of baseline PET-CT parameters with subsequent radiotherapy dose to organs in Hodgkin lymphoma

  • IRAS ID

    280718

  • Contact name

    Rebecca Shakir

  • Contact email

    rebecca.shakir@ndph.ox.ac.uk

  • Sponsor organisation

    Clinical Trials and research Governance, University of Oxford

  • Duration of Study in the UK

    1 years, 9 months, 6 days

  • Research summary

    Hodgkin lymphoma (HL) is a malignancy of the lymphatic system, predominately involving the lymph nodes. The treatment of HL is risk-adapted multi-agent chemotherapy, which may be followed by radiotherapy. HL is metabolically active, and therefore accumulates 18F-fluorodeoxyglucose (FDG). Positron emission tomography with computed tomography (PET-CT) imaging using FDG is routinely for optimal staging and treatment evaluation. With increasingly effective curative treatments, there are concerns about their long-term risks. Radiotherapy used to treat HL has been shown to cause a range of long-term side-effects that manifest many years after treatment.

    A current limitation in estimating individualised risks of radiotherapy is that the radiation dose to critical organs is not known until after the decision to use radiotherapy has already been made, and a detailed radiotherapy plan produced using a dedicated CT scan on a specialist treatment planning system.

    I will document the distribution and extent of lymph nodes involved with lymphoma from PET-CT scans from patients treated in Oxford with radiotherapy. I will use their radiotherapy plans to determine the doses subsequently received by critical organs, such as the heart, lungs and breasts. From this, I will be able to explore correlations between the distribution of lymphoma on the PET-CT scan and the radiotherapy dose the organs subsequently receive.

    I will use any identified predictors of radiotherapy doses to critical organs as inputs into statistical models to estimate individualised radiation-related risks for patients undergoing radiotherapy for lymphoma.

  • REC name

    N/A

  • REC reference

    N/A